TY - JOUR
T1 - Peptide length determines the outcome of TCR/peptide-MHCI engagement
AU - Ekeruche-Makinde, Julia
AU - Miles, John J
AU - Van Den Berg, Hugo A
AU - Skowera, Ania
AU - Cole, David K
AU - Dolton, Garry
AU - Schauenburg, Andrea JA
AU - Tan, Mai P
AU - Pentier, Johanne
AU - Llewellyn-Lacey, Sian
AU - Miles, Kim M
AU - Bulek, Anna M
AU - Clement, Mathew
AU - Williams, Tamsin
AU - Trimby, Andrew
AU - Bailey, Mick
AU - Rizkallah, Pierre J
AU - Rossjohn, Jamie
AU - Peakman, Mark
AU - Price, David A
AU - Burrows, Scott R
AU - Sewell, Andrew K
AU - Wooldridge, Linda
PY - 2013
Y1 - 2013
N2 - The alphabeta T-cell receptors (TCRs) expressed at the CD8(+) T-cell surface interact with short peptide fragments (p), bound to major histocompatibility complex class I (MHCI) molecules. The TCR/pMHCI interaction is pivotal in all aspects of CD8(+) T-cell immunity. However, the rules that govern the outcome of TCR/pMHCI engagement are not entirely understood which is a major barrier to understanding the requirements for both effective immunity and vaccination. Here, we have discovered an unexpected feature of the TCR/pMHCI interaction by showing that any given TCR exhibits an explicit preference for a single MHCI-peptide length. Agonists of non-preferred length were extremely rare, suboptimal and often entirely distinct in sequence. Structural analysis indicated that alterations in peptide length have a major impact on antigenic complexity, to which individual TCRs are unable to adapt. This novel finding demonstrates that the outcome of TCR/pMHCI engagement is determined by peptide length in addition to the sequence identity of the MHCI-bound peptide. Accordingly, the effective recognition of pMHCI antigen, which is a prerequisite for successful CD8(+) T-cell immunity and protective vaccination, can only be achieved by length-matched antigen-specific CD8(+) T-cell clonotypes.
AB - The alphabeta T-cell receptors (TCRs) expressed at the CD8(+) T-cell surface interact with short peptide fragments (p), bound to major histocompatibility complex class I (MHCI) molecules. The TCR/pMHCI interaction is pivotal in all aspects of CD8(+) T-cell immunity. However, the rules that govern the outcome of TCR/pMHCI engagement are not entirely understood which is a major barrier to understanding the requirements for both effective immunity and vaccination. Here, we have discovered an unexpected feature of the TCR/pMHCI interaction by showing that any given TCR exhibits an explicit preference for a single MHCI-peptide length. Agonists of non-preferred length were extremely rare, suboptimal and often entirely distinct in sequence. Structural analysis indicated that alterations in peptide length have a major impact on antigenic complexity, to which individual TCRs are unable to adapt. This novel finding demonstrates that the outcome of TCR/pMHCI engagement is determined by peptide length in addition to the sequence identity of the MHCI-bound peptide. Accordingly, the effective recognition of pMHCI antigen, which is a prerequisite for successful CD8(+) T-cell immunity and protective vaccination, can only be achieved by length-matched antigen-specific CD8(+) T-cell clonotypes.
UR - http://bloodjournal.hematologylibrary.org/content/121/7/1112.full.pdf
U2 - 10.1182/blood-2012-06-437202
DO - 10.1182/blood-2012-06-437202
M3 - Article
SN - 0006-4971
VL - 121
SP - 1112
EP - 1123
JO - Blood
JF - Blood
IS - 7
ER -